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1.0 Abstract
In this study, we explore the impact of gene-based patents on the pricing and
availability of genetic diagnostic tests. We also explore the nature and scope of the
genetic diagnostics industry itself. Through data mining of the GeneTests database and
gathering of pricing and procedure information from over 51 laboratories (using a range
of sources including phone interviews), we created a unique database that links pricing,
procedure and availability information for each sequencing-based gene diagnostic test
offered in the US. In addition, we linked relevant gene-based patents to each gene in our
database. Our results indicate a correlation between gene patents and test pricing, with an
average non-patented test price of -$1330.31 (121 entries) compared to an average price
of -$1419.58 for tests associated with gene patents (137 entries).
Thesis Supervisor: Fiona Murray
Title: Assistant Professor, Sloan School of Management
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3.0 Introduction
Genetic diagnostic testing involves the analysis of human genes and gene
products for the detection of disease-related alterations (1, 2). Although there are a
variety of available testing methods, most genetic diagnostic tests involve the scanning of
DNA segments (typically extracted from a blood sample) in search of mutated nucleotide
sequences. By linking nucleotide irregularities to diseases, genetic tests are great tools
for diagnosing and predicting disease.
In recent years, the size of the genetic diagnostics industry grew tremendously.
Advancements in gene sequencing technologies accelerated gene discovery and enabled a
wave of research linking genes to diseases. According to the Gene Tests database (see
www.genetests.org), there are currently 960 diseases for which clinical genetic diagnostic
testing is available.
Many of the genes associated with these genetic tests are subject to intellectual
property. Although genes may not be patented as they exist in the human body, U.S. and
European patent laws permit gene patents that claim a unique therapeutic or diagnostic
use for a gene, or a proprietary method of gene isolation (3).
The impact of gene patenting on biomedical research and clinical medicine is a
subject of considerable controversy (4). Proponents of gene patenting suggest that gene
patents provide important incentives for the on-going R&D necessary to take gene-based
ideas from the concept stage to the market and the clinic. Proponents also note the
benefits of the information disclosure which results from patents (5). Critics, however,
argue that gene patents discourage complementary R&D investments, stifle academic
research, and slow the development of new medicines (5). With regard to genetic
diagnostic testing in particular, critics argue that gene patent-related royalties result in
increased test costs and decreased test availability (6). It is this alleged connection
between gene patents and genetic diagnostic test pricing and availability that we explored
in this study as it has not been subject to large-scale empirical analysis to date.
To conduct this study, we collected information about the pricing and availability
of full-gene sequencing diagnostic tests in the United States. These are tests for which
then entire coding region of a gene is sequenced in search of disease-related mutations.
We also collected information about test procedures by analyzing the Current Procedural
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Terminology (CPT) codes associated with each gene test. In addition, we linked each
gene in our study to the corresponding number of gene patents by using a comprehensive
gene patent database from a past study (5). Our data enable a number of novel
conclusions regarding both the impact of gene patents on genetic diagnostics and the
nature of the genetic diagnostics industry itself. Our data suggest, among other things,
that gene-based patents do indeed correspond to higher test pricing.
4.0 Background
The landscape of the genetic diagnostics industry is very complex. In order to
better understand the industry and the context of our study, there are a few topics that are
of particular importance, including (1) the differences among diagnostic methodologies,
(2) the meaning and relevance of diagnostic CPT codes, (3) the heterogeneous forms in
which genetic diagnostic tests are packaged and labeled, and (4) the unique industry
structure. Also relevant to our study is a general understanding of the gene patent
landscape. Here we have researched these and other topics and outlined some of our
relevant findings.
4.1 Diagnostic Testing Methodologies
There are roughly 16 distinct methodologies by which genetic testing occurs ().
These methodologies can be broken down into four general categories:
Direct DNA Analysis:
Sequencing of entire coding region, Sequencing of select exons, Mutation
scanning, Mutation analysis, Protein Truncation Test (PTT)
DNA Analysis (Non-Direct):
Linkage analysis, Methylation analysis, Uniparental disomy (UPD), X-
chromosome inactivation study
Molecular Cytogenic Methodologies:
FISH-metaphase, FISH-interphase, Subtelomeric FISH screen, Multicolor
FISH (M-FISH)/spectral karotyping(tm) (SKY(tm))
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Biochemical Methodologies:
Analyte, Enzyme assay, Protein analysis
For many genes and diseases, there are multiple methodologies by which testing
is available. Testing for gene UBE3A (associated with Angelman syndrome), for
example, is offered in 11 distinct forms by a total of 102 labs worldwide.
However these methods vary widely in their cost and in their accuracy and the
applicability to particular mutations or diagnostic enquiries. To eliminate illegitimate
price comparisons across methodologies, we chose to limit our study to one methodology
in particular: the sequencing of the entire coding region, although we do analyze cases in
which a test is offered using full sequencing as well as other methods. Also referred to as
a full sequencing analysis or a full gene sequencing, the sequencing of the entire coding
region is a process that is thought by some to be "the gold standard of genetic testing."
(8). It is, in any case, the most thorough form of testing. Typically, a full sequence
analysis involves PCR-based nucleotide sequencing of each of a gene's exons (coding
regions) in search of sequence abnormalities.
4.2 Heterogeneous Test Packaging
In addition to diverse diagnostic methodologies, there is a great deal of diversity
in the way in which genetic tests are packaged. When we refer to test packaging, we
simply refer to the gene(s) and disease(s) to which a given genetic test applies. The
primary cause of packaging irregularities stems from the fact that some genes are
associated with multiple diseases and some diseases are associated with multiple genes.
The basic concept is illustrated by FIG. 1 below.
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FIG. 1: Diagram illustrating relationships between genes
and diseases. As shown, there are 3 diseases associated
with Gene A (Diseases A, B, and C), and there are 3 genes
associated with Disease E (Genes C, D, and E). Gene B,
however, is the only gene associated with Disease D.
The simplest case of test packaging involves the testing of a single gene which is
linked to a single disease - for example Gene B and Disease D in our Figure. A slightly
more complicated scenario occurs for testing of a single gene which is linked to multiple
diseases. In these cases, one lab may offer a test for the gene and all of its diseases, while
another lab may offer a test for the gene and only one or some of its associated diseases.
Fortunately, for our purposes in the study of full gene sequence tests, these cases can be
treated identically. Since the pricing and procedure associated with the full sequencing
and analysis of a particular gene is generally the same independent of the number of
diseases toward which testing is targeted, such variations can be neglected from our
database. Cases where multiple genes are packaged into a single test are those which
complicate our study the most. For these cases, we are generally able to collect pricing
and CPT coding information for the test as a whole. As a result, the cost and procedure
associated with each gene is unclear and the link between gene and price is blurred. In
cases such as these we have examined different specifications of our analysis to include
the number of genes included in a particular test as part of our determination of price
sensitivity.
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4.3 Diagnostic CPT Codes
The procedures involved in gene sequencing have been structured to correspond
to Current Procedural Terminology (CPT) codes. These codes serve to standardize
medical procedures for private and public health insurance reimbursement. FIG.3 lists
some of the most common codes and procedures used for gene sequencing, as well as the
associated Medicare reimbursement amounts (14).
CPT Code Procedure MedicarePayment
83890 molecular isolation or extraction $5.60
83891 isolation or extraction of highly purified nucleic acid $5.60
83892 enzymatic digestion $5.60
83893 dot/slot blot production $5.60
83894 separation by gel electrophoresis $5.60
83896 nucleic acid probe, each $5.60
83897 nucleic acid transfer $5.60
83898 amplification of patient nucleic acid, each nucleic acid $23.42
83901 amplification of patient nucleic acid, multiplex, each nucleic acid $23.42
83902 reverse transcription $19.83
83903 mutation scanning by physical properties, each single segment $23.42
83904 mutation identification by sequencing, each single segment $23.42
83905 mutation identification by allele specific transcription, each single $23.42
segment
83906 mutation identification by allele specific translation, each single $23.42
segment
83912 interpretation and report $5.60
FIG.2: CPT codes and descriptions for common molecular diagnostic
procedures. Pricing data represents Medicare national limitation
amounts (CodeMap Compliance Briefing: 4/2/2004).
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For a typical full sequence test, certain procedures are repeated several times. In
particular, procedures corresponding to codes 83898 (nucleic acid amplification), 83904
(mutation identification by sequencing) and 83894 (separation by gel electrophoresis) are
subject to numerous repetitions, although CPT code repetitions vary greatly from lab to
lab (certain labs also repeat codes such as 83891, 83903, 83892 and 83912). In some
cases, repeated procedures (or repeated CPT codes) correspond to the size of the gene to
be sequenced. For Athena Diagnostics, for example, the number of repetitions of the
83898 CPT code corresponds roughly to the number of exons of the relevant gene. Full
sequence analysis of the 13 exon GLUD1 gene, for example, is given by CPT codes
83891 x 1, 83898x 14, 83904 x 14, 83912 x 1, where 83898 repetitions yields a similar
value to total gene exons. At the Johns Hopkins Hospital DNA Diagnostic Laboratory,
83898 CPT code repetitions also correspond to gene exons. Thus, the full sequence
analysis of the 4 exon TTR gene corresponds to codes 83891 x 1, 83898 x 4, 83904 x 8,
83909 x 8, and 83912 x 1. It should be noted, however, that for many labs this direct
correlation does not exist. The reasons for these CPT coding differences are still unclear,
however we suspect that they result (1) actual differences in diagnostic procedures, and
(2) differences in the characterization of similar or identical procedures.
4.4 Market Structure and Dynamics
With genetic diagnostics, as with most areas of medicine, the road to testing
typically begins with a patient visit to the physician. If a patient is suspected of having a
particular disease, a doctor may order a relevant genetic diagnostic test if such a test
exists. A doctor may then collect the patient's genetic sample, typically by drawing a
few milliliters of blood, and send this sample to the appropriate diagnostic laboratory for
analysis. Such laboratories often provide doctors with a kit to assist in the shipment
process. Both Athena Diagnostics and GeneDx, Inc., for example, provide clients with
custom shipping kits free of charge. Once the sample is received by the diagnostic
laboratory, the sample is analyzed, the patient (and insurance company) is billed, and the
results are reported to the patient's doctor.
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Sample Market Flow Chart
FIG.3: In this sample flow chart, we see the case where Diagnostic Laboratory 1 has
been granted an exclusive license for a test by the Patent Holder, and then sublicensed
the test to Diagnostic Laboratory 2.
Although this may sound straightforward, there are an array of nuances and
various other types of companies which complicate this overview. To illustrate the
structure and dynamics of this market, let's consider the development of a genetic test for
Severe Myoclonic Epilepsy of Infants (SMEI) which involves the sequencing of the
SCN1A gene. The SCN1A sequencing test was the first genetic test for SMEI and was
developed by Australia-based Bionomics Ltd in collaboration with researchers based at
the University of Melbourne and at the Adelaide Women's and Children's Hospital (13).
In September of 2004, Bionomics licensed their SMEI test to Athena Diagnostics,
a U.S.-based diagnostic company focused on neurological genetic tests. According to the
Bionomics press release, Athena Diagnostics was granted permission to market the test in
to neurologists in North America and Japan. With more than 45 sales representatives in
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the U.S. alone, Athena planned to provide the test to a group of more than 5,000
neurologists for whom they already performed diagnostic testing (12). The terms of the
license called for an upfront payment by Athena, as well as "milestone payments linked
to sales targets and royalty payments on net sales" (10). Later, in November of 2004,
Bionomics reached another SMEI-related agreement, this time with Australia-based
Genetic Technologies Limited (GTG). Under the terms of this agreement, GTG was
given permission to market worldwide through the Gendia laboratory network. Athena's
test, which involves the detection of SCN1A sequence variations, is currently offered in
the U.S. at a price of $3995.
Generally speaking, the majority of genetic diagnostic discoveries are made by
academic institutions. It is not surprising, then, that Bionomic's SCN1A discovery came
in collaboration with the University of Melbourne and at the Adelaide Women's and
Children's Hospital. Indeed, such partnerships between academia and industry are
common, as private companies benefit from government-funded R & D while academic
institutions benefit financially when their patented tests are made commercial available.
As another example such a partnership, Bionomics has since announced a diagnostic
research collaboration with Emory University. According to a Bionomics press release,
both Bionomics and Emory University "will jointly own the intellectual property arising
from the epilepsy research while Bionomics, Inc. will have exclusive rights relating to the
commercialization of that intellectual property" (11)
4.5 Diagnostic Test Pricing
Also relevant to our study is an understanding of the various factors which
influence genetic test pricing. On the basis of a series of interviews with industry
executives, we found that both gene size and test methodology are very important factors
in determining price, where increased size typically corresponds to increased price.
Other important factors include pricing objectives for the test provider, external market
factors (such as number of potential patients), R & D compensation and, as we
hypothesize, patent related royalties. An illustration of these influences can be seen
below in FIG.4.
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FIG.4: This diagram offers a very simplified illustration of the
factors which effect genetic test pricing.
5.0 Related Work
To date, no study has linked patents to genes and diagnostic tests. Past analyses
regarding the impact of gene patents on genetic diagnostics have been limited primarily
to anecdotal evidence. As a result, there is little information regarding the extent to
which gene patents effect genetic diagnostic test pricing and availability.
In 2003, Cho and a group of Stanford University researchers published a study on
the topic of gene patents and genetic diagnostics (15). Cho et al surveyed 201 genetic
laboratory directors via telephone with questions regarding the impact of gene patents of
diagnostic testing. According to the study, 53 % of respondents reported that they had
decided not to offer a genetic diagnostic test because of a patent or license, and 25%
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reported that they had actually stopped offering a genetic diagnostic test because of a
patent or license. The study also noted that most respondents had a negative perception
of the role of patents on the price, availability and development of genetic tests but was
not designed to probe this relationship more deeply.
In 2005, a study by Kyle Jensen and Fiona Murray of MIT provided a
comprehensive map of the human genome patent landscape (5). This study linked gene
patents, patent holders, and genome location, among other things. The study revealed
that nearly 20% of the human genome has already been patented, and that a
disproportionately high number of those patents pertain to disease-related genes.
6.0 Methods
To begin this study, we first researched the genetic diagnostics industry. As
mentioned in our background section, the primary challenges of this process were (1)
understanding the market structure, (2) understanding the differences between diagnostic
methodologies, (3) understanding the meaning and relevance of diagnostic CPT codes,
and (4) understanding the heterogeneities of genetic diagnostic tests themselves. We also
researched the history and extent of the gene patent landscape.
With a general understanding of the industry, we then created the framework for
our database. Using the software written by our team, data was taken from the Gene
Tests database and placed into a Microsoft Excel spreadsheet for analysis (see section 5.0
for more detail on this procedure). As a result, our preliminary database included
information about each gene, disease and test provider in the Gene Tests database. The
structure of our database is pictured below in FIG. 5 (note that CPT codes and prices are
included here, although they were not included at this stage of the study). Each row, or
entry, features a disease, a corresponding gene and a corresponding test provider. For
example, if a given disease has 3 associated genes and there 3 test providers which test
for this disease, there will be a total of 9 entries. Likewise, there will be 9 entries for a
single gene which has 3 associated diseases and 3 test providers (maybe modify this
statement).
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In all, there were 7195 entries in this database, with 795 distinct diseases and 864
distinct genes. To eliminate faulty price comparisons between different test
methodologies, we decided to focus our study on tests for which at lease one U.S. test
provider employs the full gene sequencing methodology. In addition, we decided to
focus only on tests offered in the United States. To isolate this data subset, we sorted our
preliminary database by methodology and test location. The resulting subset consisted of
832 entries, 364 distinct diseases and 377 distinct genes.
With this subset of data, we were then able to provide information about the
availability of each test. This was accomplished by using Microsoft Excel to count the
number of times that each test was repeated in the database, thus revealing the number of
labs at which the test is available. A simplified sample of this modified database
(including CPT codes and pricing) is featured in FIG.4.
Disease Name Gene Test Provider CPT Codes Test Price
Johns Hopkins Hospital, DNATransthyretin Amyloidosis TR 83891 x 1, 83898 x 4.83904 x 8.Transthyretin Amyloidosis TR Diagnostic Laboratory 83909 x 8. 83912 x I 662
APC-Associated Polyposis APC Baylor College of Medicine 83891 x 1. 83898 x 28, 83904 x 56, 1500
Conditions Medical Genetics Laboratory 83894 x 56. 83912 x 1
Multiple Endocrine Neoplasia RETGeneDx, Inc 83891 x 8 83898 x 8 83894x 8. 650
Type 2 83904 x 8, 83892 x 2. 83912 x 2
Familial Cerebral Cavernous CCM 83890 x 1. 83891 x . 83898 x 16. 1090
Malformation 1 CCMl PreventionGenetics 83904 x 16, 83894 x 1. 83914 x 
Familial Cerebral Cavernous 83890 x 1, 83891 x 1. 83898 x 10.
Malformation 2 CCM2 PreventionGenetics 83904 x 10. 83894 x 1. 83914 x 1 740
Familial Cerebral Cavernous CCM3 83890 x 1. 83891 x . 83898 x 7.
Malformation 3 83904 x 7, 83894 x 1. 83914 x 1
Rapid-Onset Dystonia ATPIA3 Massachusetts General Hospital 83891 x 1, 83898 x 2. 83904 x 2.
Parkinsonism / Harvard Medical School 83891 x I
MTTS1 -Related Hearing Loss and Harvard-Partners Center for 83891 x 1, 83894 x 1. 83898 x 2.
Deafness Genetics and Genomics 83904 x 3. 83912 x 
FIG.5: Sample of genetic test database information
With our Excel database serving as a framework, our next challenge was to map
each test to the corresponding CPT codes and prices. This was accomplished, in part, by
searching through test provider websites for CPT code and price listings. A large portion
of CPT code and pricing information was also collected through phone conversations
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with test provider representatives. While accumulating prices and CPT codes, 39 of the
377 genes were eliminated from our study. In some cases, genes were eliminated
because we were unable to find evidence of US-based full sequence testing. We also
eliminated all mitochondrial genes from our study, leaving us with a group of 338 nuclear
genes for which full sequencing testing is available in the US. [can you explain why?].
After collecting CPT code and pricing information, we then listed the number of
patents associated with each gene in our database. To match genes to patents, we used a
comprehensive gene patent database from a past study (5).
Our final database listed the following information for each entry: gene, number
of gene patents, associated disease, number of laboratories (availability), laboratory (for
particular entry), test price and CPT codes.
7.0 Design Component
For the design component of this project, we created a suite of software
comprising a set of Unix shell scripts and a Python program to extract information from
the GeneTests Database and transfer the information into a Microsoft Excel Spreadsheet.
This program, which was central to our database assembly, is designed so that it can also
be used to update our database in the future as new tests are added to the GeneTests
Database, or changes are made. Featured below is FIG.6 is a diagram which follows the
flow of information from the GeneTests database to our Excel spreadsheet as generated
by our software.
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FIG.6: Diagram illustrating the flow of information as a result of
designed software. Note that the software, which consists of Unix shell
scripts and a Python program, can be used to update our database as
more tests are added to the GeneTests database.
For each entry listed in the GeneTests Database, our program extracted 34 unique
sets of data, including the gene symbol, gene locus, associated protein, disease name,
institution (test provider), and location of test provider. Although GeneTests is a publicly
available source of information, the underlying data are not available to researchers in a
batch download, nor are the data exposed via an Application Programming Interface
(API). Therefore, we had to download each of the HTML-formatted pages on the
GeneTests site and parse the data using a series of regular expression-based functions to
match particular patterns and build a local database of tests.
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6.0 Results and Discussion
Our final database consists of the 338 nuclear genes for which US-based full
sequence testing is available. Our pricing data comes from 51 institutions, with a large
portion of data coming from GeneDx, Inc., Athena Diagnostics and the Baylor College of
Medicine (-45 % of entries).
Most of our data analysis was done using a subset of this data: a group of 257
tests for which we have collected pricing information. Note that a group of tests differs
from a group of genes in that a group of tests includes both tests that correspond to one
gene and tests that correspond to multiple genes (packaged tests). As a result, our group
of 257 tests actually corresponds to 274 of the 338 nuclear genes for which US-based full
sequence testing is available (81 %). Of the 257 tests, 246 are tests of a single gene (95.3
%), while 12 are packaged tests with multiple genes (4.7 %). In some cases, for a single
test, pricing and CPT code information was collected from multiple laboratories. For
these tests, we averaged our collected prices and used this averaged value as a single data
point.
For tests not included in this subset, reasons for exclusion include: (1) inability to
contact test providers, (2) unwillingness of test providers to reveal CPT codes and pricing
information, and (3) cases where test relevance to dataset is still under review (for
example, cases where it is still unclear whether full sequence testing is available).
Featured below is a table which summarizes the general results for several
categories of data. The data subset used for this table is the group of 257 tests previously
mentioned.
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Data Table for 257 Tests (both Patented and Unpatented Tests)
Standard Maximum MinimumParameter (per Test) Average Deviation Value Value
Price (USD) $1378.95 $794.78 $5400 $126.50
#of Exons 14.5573123 13.54247 79 1
Price per Exon (USD) $144.05 $118.77 $925 $13.04
# of Genes per Test 1.08560311 0.468194 5 1
# of Exons per Gene 13.8196311 12.61522 79 1
# of Patents 1.31128405 2.589867 20 0
# of Test Providers 2.26459144 3.533328 40 1
FIG.7: Table ofaverages, standard deviations, maximum values and minimum values
from a group of data parameters collected during the study.
In addition, we have summarized our data for tests with associated patents and
tests without associated patents. These data summaries can be seen in FIG.8 (Patented
Tests) and FIG.9 (Unpatented Tests). Note that both datasets come from our list of 257
sets, where the patented data contains 121 tests and the unpatented data comes from 136
tests.
Data Table for Patented Tests (121 entries)
Standard Maximum Minimum
Parameter (Per Test) Average Deviation Value Value
Price (USD) $1419.58 $858.02 $5400 126.50
# of Exons 15.0336134 14.42745 79 1
Price per Exon (USD) $147.42 $129.44 $925 $31.65
# of Genes per Test 1.10743802 0.513187 5 1
# of Exons per Gene 13.7957983 12.62964 79 1
# of Patents 2.78512397 3.189061 20 1
# of Test Providers 2.33057851 3.364987 32 1
FIG.8: Table of averages, standard deviations, maximum values and minimum vahlies
from a group of data parameters collected for patented tests.
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Data Table for Unpatented Tests (136 entries)
Standard Maximum Minimum
Parameter (Per Test) Average Deviation Value ValueDeviation Value Value
Price (USD) $1330.31 $733.75 $3995 $300
# of Exons 14.1343284 12.74492 67 1
Price per Exon (USD) $141.07 $108.83 $795 $13.04
# of Genes per Test 1.06617647 0.425175 5 1
# of Exons per Gene 13.840796 12.64975 67 1
# of Patents 0 0 0 0
# of Test Providers 2.20588235 3.688054 40 1
FIG.9: Table of averages, standard deviations, maximum values and minimum values
from a group of data parameters collected for unpatented tests.
One result that stands out from these data is the difference in price of patented vs.
unpatented tests. Our results show that the average price of an unpatented test is
$1330.31, while the average patented test price is $1419.58, an average difference of
almost $90. Our data also shows a difference in the average price per exon for patented
and unpatented tests. The average price per exon for unpatented tests is $141.07,
compared to $147.42 for patented tests.
With regard to CPT coding, FIG.8 below shows the frequency with which
particular diagnostic CPT codes are used. The first column lists the diagnostic CPT
codes originally listed in FIG.2, and the second column lists the number of tests which
use each CPT code from our group of 257 tests.
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CPT Code Number of Tests which Use Code
83898 224
83904 219
83912 215
83891 180
83894 130
83892 72
83890 62
83903 13
83902 5
83901 2
83896 1
83893 0
83895 0
83897 0
83905 0
83906 0
FIG. 10. Table of diagnostic CPT codes which indicates
the number of tests which use each code. Note that this
list is not comprehensive, as unlisted CPT codes are used
for genetic diagnostic testing in some cases.
This table indicates that certain diagnostic CPT codes are used much more
frequently than others. CPT codes 83898, 83904, 83912, 83891, and 83894 used in more
50 % of tests, while CPT codes 83893, 83895, 83897, 83905 and 83906, are not used in
any tests.
General Test Pricing and Availability Data
For the group of 257 tests for which we collected pricing information, we found
the average test price to be $1378.95. As seen below in FIG.11, when sorted as a
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histogram in increments of $250, the largest portion of tests falls in the $1000-$1250
range.
FIG. 11: This figure shows the number of tests for each price range. The data comes
from the subset of 257genetic tests for which pricing information has been collected.
In terms of test availability, we found that more than half of all tests are offered
by one lab (57%), and that this percentage decreases steadily as the number of
laboratories increases. FIG. 11 below illustrates these data in the form of a pie chart. We
also found that the average test is offered by 2.27 laboratories, with a range from 1 to 40.
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Number of Tests vs. Price Range
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FIG.12: This figure shows the percentage ofgenetic tests offered for by a given number
of labs. The data set for this graph is the list of 257 unique gene tests for which pricing
information has been collected.
Of these tests, we found six tests for which full sequence testing is available at ten
or more laboratories. FIG. 13 below provides information for each of these popular six
tests, including the number of laboratories (test providers), the number of associated
patents, the gene symbol, and the associated disorder(s). Note that three of these tests
have one associated patent while the other three are unpatented.
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FIG.13: This table provides information about the 6 most widely available genetic
diagnostic tests from our group of 257 tests.
Patents and Test Pricing
As mentioned above, we found the average price for patented tests to be
$1419.58, compared to $1330.31 for unpatented tests. In addition, we found the average
price per exon for patented and unpatented tests to be $147.42 and $141.07 respectively.
To take a closer look at these data, we plotted separate histograms the number of tests vs.
test price range (sorted in increments of $250) for patented tests and unpatented tests.
These plots can be seen in FIG.14 and FIG.15 below.
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Patented Tests - Number of Tests vs. Price Range
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FIG. 14: This histogram shows the number of patented tests for each price range in
increments of $250. Like the histogram for all 257 tests, the largest category is the
$1000-$1250 range.
FIG. 15: This histogram shows the number of unpatented tests for each price range in
increments of $250. When compared to the patented test histogram, we can see that in
the unpatented test histogram the three categories that span the $250-$1000 price range
each have a higher number of entries. It should be noted; there are 15 more unpatented
tests overall.
24
Unpatented Tests - Number of Tests vs. Price Range
Number
of Tests
0-250 250- 500- 750- 1000- 1250- 1500-1750-2000-2250 -2500- 2750
500 750 1000 1250 1500 1750 2000 2250 2500 2750 +
Price Range (USD)
i;.. ..-- .. ... .
When sorted by number of patents, the averaged test price values support a
correlation between patents and test pricing. In FIG. 16 below, we can see the average
price for tests with each number of associated patents, along with the corresponding
standard deviation for each of those averaged values.
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FIG.16: This histogram shows the relationship between the number of associatedgene
patents and test price. The error bars represent one standard deviation in each direction.
Similarly, FIG. 17 shows the average price per exon for tests with each number of
associated patents, along with the corresponding standard deviation for each of those
averaged values. Here, however, the relationship between price per exon and number of
patents is not particularly apparent, despite the overall difference that exists for the
average price per exon for unpatented and patented tests.
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FIG.17: This histogram shows the relationship between the number of associated gene
patents and the price per exon. The error bars represent one standard deviation in each
direction.
Gene Size and Price
Our results also indicate that test prices increases as a result of increased gene size
(number of exons). This result is predictable given that each sequenced exon requires an
additional set of procedures which takes additional time and costs additional money for
test providers. FIG. 18 below demonstrates this relationship with a graph of test price vs.
number of exons for our group of 257 tests.
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FIG. 18: This graph demonstrates the relationship between test price and number of
exons. As shown, the applied best fit line has a slope of-40.
As we would expect, this result is consistent with data taken exclusively from
Athena Diagnostics. As seen in FIG.19 below, this group of 49 Athena Diagnostics tests
shows a similar trend to that of the entire dataset.
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Test Price vs. Number of Exons
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FIG. 9: This graph shows that for the of 49 tests at thena Diagnostics, larger genes in
terms of number of exons) tend to correspond to more expensive tests. These results are
consistent with that of the entire dataset.
Economies of Scale
We have also found that for a given test, the price per exon tends to decrease as
the number of exons increases. This result can be seen in FIG.20 below, which
represents data from our list of 257 tests for which we collected pricing information.
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Price Per Exon vs. Number of Exons
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FIG.20: This graph shows the relationship between the price per exon and the total
number of exons for full gene sequence tests. As we can see, the price per exon tends to
decrease as the number of exons to be sequenced increases.
Again, this result is consistent with the Athena Diagnostics dataset. As seen in
FIG.21 below, this group of 49 Athena Diagnostics tests shows a similar trend to that of
the larger dataset.
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FIG.21: This graph shows the relationship between price per exon and number of exons
for a set of 49 tests offered at Athena Diagnostics. Similar to the data the entire group of
tests, these data show a trend whereby price per exons decreases as the number of exons
increases.
Laboratory Consistency
In addition, we have collected multiple data points for several of the genes in our
database. For these genes, where pricing and CPT codes are listed from multiple
laboratories, we were able to analyze the consistency of pricing and CPT coding across
laboratories.
To study test price and procedure consistency across laboratories, we focused on
the 4 four genes for which we collected the most information: MECP2, PTPN11, GJB2,
and LMNA.
For the MECP2 gene, we collected pricing information from 5 laboratories and
found a price range from $925 to $1092. The average of these prices is $1022.77, with a
standard deviation of $70.39. For the PTPN11 gene, data was collected from 4
laboratories, with a price range from $1750 to $950. The average of these prices is
$1287.5, with a standard deviation of $402.85. For the LMNA gene, we collected pricing
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information from 5 laboratories and found a price range from $575 to $1009. The
average of these prices is $814.75, with a standard deviation of $186.56. Lastly, data
taken from 6 laboratories for the GJB2 showed more consistent results, with a price range
from $290 to $450, an average of $367.67, and a standard deviation of $68.30.
These results illustrate the highly varied nature of test pricing across laboratories.
For the four genes studies, our results indicate an average range of -$390 and an average
standard deviation of -$182.
CPT coding also seems to be highly varied across laboratories. This concept can
be seen in FIG.X, where the CPT codes for five test providers are drastically different for
the MECP2 full gene sequencing test.
FIG.22: This chart shows the variations in CPT coding and pricing for the full
sequencing test of the MECP2 gene. We can see that for this test CPT coding is
particularly varied. As shown, each of the five test providers differ in terms of CPT codes
used and number of repetitions per code.
7.0 Conclusions
Overall, our data indicate that there is a correlation between increased gene-based
patents and increased genetic diagnostic test pricing. From our dataset of 257 U.S.-based
full sequence genetic tests, we found the average price for patented tests to be $1419.58
and the average unpatented test price to be $1330.31. In addition, we found the average
price per exon for patented and unpatented tests to be $147.42 and $141.07 respectively.
There are several ways in which our study can be improved in the future. To
begin with, we can collect more pricing data per test in order to make our pricing values
more reliable. As seen in our "Laboratory Consistency" results section, there is a great
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deal of variability both in pricing and CPT coding across laboratories. With more data
for each test we may see more consistency in our results. Another potential improvement
may come from determining which gene-based patents actually generate royalties
through diagnostic-related licensing. Although our list of gene patents tells us how many
times each diagnostic-related gene has been patented, applying a more refined list of
royalty-generating diagnostic gene patents may yield more consistent results as well.
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